Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Exceso de peso en España: situación actual, proyecciones para 2030 y sobrecoste directo estimado para el Sistema Nacional de Salud, Excess weight in Spain: current situation, projections for 2030, and estimated direct extra cost for the Spanish Health System

  • Hernáez, Álvaro
  • Zomeño, M. Dolores
  • Degano, Irene R.
  • Pérez Fernández, Sílvia
  • Goday, Alberto
  • Vila, Joan
  • Civeira, Fernando
  • Moure, Ricardo
  • Marrugat, Jaume
Introducción y objetivos El exceso de peso potencia algunas enfermedades crónicas y reduce la calidad de vida, y su prevalencia crece en todo el mundo. El objetivo es estimar la evolución del exceso de peso entre 1987 y 2014 en población española adulta, calcular los casos de exceso de peso y sus sobrecostes médicos directos en 2006 y 2016, y proyectar su tendencia a 2030. Métodos Se seleccionaron 47 artículos en una búsqueda bibliográfica sistemática para determinar la progresión de las prevalencias de sobrepeso, obesidad y obesidad mórbida y del índice de masa corporal promedio entre 1987 y 2014. Con estos datos, se estimó el número de casos en adultos españoles en 2006, 2016 y 2030 y sus sobrecostes directos. Resultados Entre 1987 y 2014, las prevalencias de sobrepeso, obesidad y obesidad mórbida aumentaron el 0,28%/año (p=0,004), el 0,50%/año (p<0,001) y el 0,030%/año (p=0,006) en los varones y el 0,10%/año (p=0,123), el 0,25%/año (p=0,078) y el 0,042%/año (p=0,251) en las mujeres. El índice de masa corporal aumentó 0,10 puntos/año en varones (p<0,001) y 0,26 en mujeres (significativamente solo entre 1987-2002, p <0,001). Se estimaron 23.500.000 casos de exceso de peso en 2016, cuyo sobrecoste médico directo supuso 1.950.000.000 euros/año. De mantenerse la tendencia, entre 2016 y 2030 aparecerán 3.100.000 nuevos casos de exceso de peso, y se alcanzará en 2030 un sobrecoste médico directo de unos 3.000.000.000 euros/año. Conclusiones El exceso de peso en los adultos en España aumenta desde que existen registros, y en 2016 supuso un sobrecoste directo del 2% del presupuesto sanitario. Con esta tendencia, en 2030 se habrá incrementado un 16% el número de casos y un 58% su sobrecoste sanitario directo., Introduction and objectives Excess weight promotes the development of several chronic diseases and decreases quality of life. Its prevalence is increasing globally. Our aim was to estimate the trend in excess weight between 1987 and 2014 in Spanish adults, calculate cases of excess weight and its direct extra costs in 2006 and 2016, and project its trend to 2030. Methods We selected 47 articles in a systematic literature search to determine the progression of the prevalence of overweight, nonmorbid obesity, and morbid obesity and average body mass index between 1987 and 2014. We projected the expected number of cases in 2006, 2016, and 2030 and the associated direct extra medical costs. Results Between 1987 and 2014, the prevalence of overweight, obesity, and morbid obesity increased by 0.28%/y (P=.004), 0.50%/y (P <.001) and 0.030%/y (P=.006) in men, and by 0.10%/y (P=.123), 0.25%/y (P=.078), and 0.042%/y (P=.251) in women. The mean body mass index increased by 0.10 kg/m2/y in men (P <.001) and 0.26 kg/m2/y in women (significantly only between 1987 and 2002, P <.001). We estimated 23 500 000 patients with excess weight in 2016, generating 1.95 billion €/y in direct extra medical costs. If the current trend continues, between 2016 and 2030, there will be 3 100 000 new cases of excess weight, leading to 3.0 billion €/y of direct extra medical costs in 2030. Conclusions Excess weight in Spanish adults has risen since the creation of population registries, generating direct extra medical costs that represent 2% of the 2016 health budget. If this trend continues, we expect 16% more cases in 2030 and 58% more direct extra medical costs., info:eu-repo/semantics/acceptedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Increased consumption of virgin olive oil, nuts, legumes, whole grains, and fish promotes HDL functions in humans

  • Hernáez, Álvaro
  • Sanllorente Melenchon, Albert
  • Castañer, Olga
  • Martínez-González, Miguel Ángel, 1957-
  • Ros Rahola, Emilio
  • Pintó Sala, Xavier
  • Estruch Riba, Ramon
  • Salas Salvadó, Jordi
  • Corella Piquer, Dolores
  • Alonso Gómez, Ángel M.
  • Serra Majem, Lluís
  • Fiol, Miquel
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • de la Torre, Rafael
  • Lamuela Raventós, Rosa Ma.
  • Fitó Colomer, Montserrat
Scope To evaluate whether increases in the consumption of cardioprotective food groups (virgin olive oil, nuts, fruits/vegetables, legumes, whole grains, fish, and wine) are associated with improvements in high-density lipoprotein (HDL) functions in high cardiovascular risk subjects. Methods and Results The association between 1-year changes in food group consumption and HDL functionality traits in 296 high cardiovascular risk subjects is assessed. Increases in virgin olive oil (10 g d–1) and whole grain consumption (25 g d–1) are associated with increments in cholesterol efflux capacity (+0.7%, P = 0.026, and +0.6%, P = 0.017, respectively). Increases in nut (30 g d–1) and legume intake (25 g d–1) are linked to increments in paraoxonase-1 activity (+12.2%, P = 0.049, and +11.7%, P = 0.043, respectively). Legume intake increases are also related to decreases in cholesteryl ester transfer protein activity (–4.8%, P = 0.028). Fish consumption increments (25 g d–1) are associated with increases in paraoxonase-1 activity (+3.9%, P = 0.030) and declines in cholesteryl ester transfer protein activity (–1.6%, P = 0.021), HDL cholesterol concentrations (–1.1%, P = 0.039), and functions related to HDL levels (cholesterol efflux capacity, –1.1%, P = 0.010). Conclusion Increases in the consumption of virgin olive oil, nuts, legumes, whole grains, and fish (achievable through a regular diet) were associated with improvements in HDL functions in high cardiovascular risk subjects., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Exceso de peso en España: situación actual, proyecciones para 2030 y sobrecoste directo estimado para el Sistema Nacional de Salud, Excess weight in Spain: current situation, projections for 2030, and estimated direct extra cost for the Spanish Health System

  • Hernáez, Álvaro
  • Zomeño, M. Dolores
  • Degano, Irene R.
  • Pérez Fernández, Sílvia
  • Goday, Alberto
  • Vila, Joan
  • Civeira, Fernando
  • Moure, Ricardo
  • Marrugat, Jaume
Introducción y objetivos El exceso de peso potencia algunas enfermedades crónicas y reduce la calidad de vida, y su prevalencia crece en todo el mundo. El objetivo es estimar la evolución del exceso de peso entre 1987 y 2014 en población española adulta, calcular los casos de exceso de peso y sus sobrecostes médicos directos en 2006 y 2016, y proyectar su tendencia a 2030. Métodos Se seleccionaron 47 artículos en una búsqueda bibliográfica sistemática para determinar la progresión de las prevalencias de sobrepeso, obesidad y obesidad mórbida y del índice de masa corporal promedio entre 1987 y 2014. Con estos datos, se estimó el número de casos en adultos españoles en 2006, 2016 y 2030 y sus sobrecostes directos. Resultados Entre 1987 y 2014, las prevalencias de sobrepeso, obesidad y obesidad mórbida aumentaron el 0,28%/año (p=0,004), el 0,50%/año (p<0,001) y el 0,030%/año (p=0,006) en los varones y el 0,10%/año (p=0,123), el 0,25%/año (p=0,078) y el 0,042%/año (p=0,251) en las mujeres. El índice de masa corporal aumentó 0,10 puntos/año en varones (p<0,001) y 0,26 en mujeres (significativamente solo entre 1987-2002, p <0,001). Se estimaron 23.500.000 casos de exceso de peso en 2016, cuyo sobrecoste médico directo supuso 1.950.000.000 euros/año. De mantenerse la tendencia, entre 2016 y 2030 aparecerán 3.100.000 nuevos casos de exceso de peso, y se alcanzará en 2030 un sobrecoste médico directo de unos 3.000.000.000 euros/año. Conclusiones El exceso de peso en los adultos en España aumenta desde que existen registros, y en 2016 supuso un sobrecoste directo del 2% del presupuesto sanitario. Con esta tendencia, en 2030 se habrá incrementado un 16% el número de casos y un 58% su sobrecoste sanitario directo., Introduction and objectives Excess weight promotes the development of several chronic diseases and decreases quality of life. Its prevalence is increasing globally. Our aim was to estimate the trend in excess weight between 1987 and 2014 in Spanish adults, calculate cases of excess weight and its direct extra costs in 2006 and 2016, and project its trend to 2030. Methods We selected 47 articles in a systematic literature search to determine the progression of the prevalence of overweight, nonmorbid obesity, and morbid obesity and average body mass index between 1987 and 2014. We projected the expected number of cases in 2006, 2016, and 2030 and the associated direct extra medical costs. Results Between 1987 and 2014, the prevalence of overweight, obesity, and morbid obesity increased by 0.28%/y (P=.004), 0.50%/y (P <.001) and 0.030%/y (P=.006) in men, and by 0.10%/y (P=.123), 0.25%/y (P=.078), and 0.042%/y (P=.251) in women. The mean body mass index increased by 0.10 kg/m2/y in men (P <.001) and 0.26 kg/m2/y in women (significantly only between 1987 and 2002, P <.001). We estimated 23 500 000 patients with excess weight in 2016, generating 1.95 billion €/y in direct extra medical costs. If the current trend continues, between 2016 and 2030, there will be 3 100 000 new cases of excess weight, leading to 3.0 billion €/y of direct extra medical costs in 2030. Conclusions Excess weight in Spanish adults has risen since the creation of population registries, generating direct extra medical costs that represent 2% of the 2016 health budget. If this trend continues, we expect 16% more cases in 2030 and 58% more direct extra medical costs., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Increased consumption of virgin olive oil, nuts, legumes, whole grains, and fish promotes HDL functions in humans

  • Hernáez, Álvaro
  • Sanllorente Melenchon, Albert
  • Castañer, Olga
  • Martínez-González, Miguel Ángel, 1957-
  • Ros Rahola, Emilio
  • Pintó Sala, Xavier
  • Estruch Riba, Ramon
  • Salas Salvadó, Jordi
  • Corella Piquer, Dolores
  • Alonso Gómez, Ángel M.
  • Serra Majem, Lluís
  • Fiol, Miquel
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • de la Torre, Rafael
  • Lamuela Raventós, Rosa Ma.
  • Fitó Colomer, Montserrat
Scope To evaluate whether increases in the consumption of cardioprotective food groups (virgin olive oil, nuts, fruits/vegetables, legumes, whole grains, fish, and wine) are associated with improvements in high-density lipoprotein (HDL) functions in high cardiovascular risk subjects. Methods and Results The association between 1-year changes in food group consumption and HDL functionality traits in 296 high cardiovascular risk subjects is assessed. Increases in virgin olive oil (10 g d–1) and whole grain consumption (25 g d–1) are associated with increments in cholesterol efflux capacity (+0.7%, P = 0.026, and +0.6%, P = 0.017, respectively). Increases in nut (30 g d–1) and legume intake (25 g d–1) are linked to increments in paraoxonase-1 activity (+12.2%, P = 0.049, and +11.7%, P = 0.043, respectively). Legume intake increases are also related to decreases in cholesteryl ester transfer protein activity (–4.8%, P = 0.028). Fish consumption increments (25 g d–1) are associated with increases in paraoxonase-1 activity (+3.9%, P = 0.030) and declines in cholesteryl ester transfer protein activity (–1.6%, P = 0.021), HDL cholesterol concentrations (–1.1%, P = 0.039), and functions related to HDL levels (cholesterol efflux capacity, –1.1%, P = 0.010). Conclusion Increases in the consumption of virgin olive oil, nuts, legumes, whole grains, and fish (achievable through a regular diet) were associated with improvements in HDL functions in high cardiovascular risk subjects., info:eu-repo/semantics/acceptedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction

  • Fernández-Bergés, Daniel|||0000-0002-9561-2901
  • Degano, Irene R.|||0000-0003-1914-6934
  • Gonzalez Fernandez, Reyes
  • Subirana, Isaac|||0000-0003-1676-0197
  • Vila, Joan
  • Jiménez-Navarro, Manuel|||0000-0002-6759-0514
  • Pérez-Fernández, Silvia|||0000-0002-9756-0092
  • Roqué, Mercè
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Fernández Avilés, Francisco|||0000-0001-5501-5275
  • Mayorga, Antonio
  • Bertomeu-González, Vicente|||0000-0001-5309-0562
  • Sanchis, Juan|||0000-0003-0797-8709
  • Rodríguez Esteban, Marcos
  • Sánchez Hidaldo, Antonio|||0000-0003-0710-3160
  • Sanchez-Insa, Esther
  • Elorriaga, Ane
  • Abu-Assi, Emad|||0000-0003-1568-3118
  • Nuñez, Alberto
  • Garcia Ruiz, Jose Manuel
  • Morrondo Valdeolmillos, Pedro
  • Bosch-Portell, Daniel
  • Lekuona, Iñaki
  • Carrillo-Lopez, Andres
  • Zamora, Alberto|||0000-0001-6907-0654
  • Vega-Hernandez, Berta
  • Alameda Serrano, Javier
  • Rubert, Catalina
  • Ruiz-Valdepeñas, Luis
  • Quintas, Laura
  • Rodríguez-Padial, Luis|||0000-0002-5783-3922
  • Vaquero, Jessica
  • Martinez Dolz, Luis
  • Barrabés, José A.|||0000-0001-7062-6277
  • Sánchez Fernández, Pedro Luis|||0000-0002-1402-0526
  • Sionis, Alessandro|||0000-0003-0843-9512
  • Martí Almor, Julio|||0000-0001-9927-1190
  • Elosua, Roberto|||0000-0001-8235-0095
  • Lidón, Rosa María|||0000-0001-7008-2716
  • García-Dorado, David|||0000-0002-1126-1279
  • Marrugat, Jaume|||0000-0003-3320-554X
Primary percutaneous coronary intervention (P-PCI) has demonstrated its efficacy in patients with ST segment elevation myocardial infarction (STEMI). However, patients with STEMI ≥75 years receive less P-PCI than younger patients despite their higher in-hospital morbimortality. The objective of this analysis was to determine the effectiveness of P-PCI in patients with STEMI ≥75 years. We included 979 patients with STEMI ≥75 years, from the ATención HOspitalaria del Síndrome coronario study, a registry of 8142 consecutive patients with acute coronary syndrome admitted at 31 Spanish hospitals in 2014-2016. We calculated a propensity score (PS) for the indication of P-PCI. Patients that received or not P-PCI were matched by PS. Using logistic regression, we compared the effectiveness of performing P-PCI versus non-performance for the composite primary event, which included death, reinfarction, acute pulmonary oedema or cardiogenic shock during hospitalisation. Of the included patients, 81.5 % received P-PCI. The matching provided two groups of 169 patients with and without P-PCI. Compared with its non-performance, P-PCI presented a composite event OR adjusted by PS of 0.55 (95% CI 0.34 to 0.89). Receiving a P-PCI was significantly associated with a reduced risk of major intrahospital complications in patients with STEMI aged 75 years or older.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Phenol-Enriched Virgin Olive Oil Promotes Macrophage-Specific Reverse Cholesterol Transport In Vivo

  • Cedó, Lídia|||0000-0003-4354-3411
  • Fernández-Castillejo, Sara|||0000-0002-8109-9713
  • Rubió, Laura
  • Metso, Jari
  • Santos, David|||0000-0003-1157-4969
  • Muñoz Aguayo, Daniel|||0000-0001-8173-0168
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Motilva, Maria-José|||0000-0001-8985-7737
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Solà, Rosa|||0000-0002-8359-235X
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
The intake of olive oil (OO) enriched with phenolic compounds (PCs) promotes ex vivo HDL-mediated macrophage cholesterol efflux in humans. We aimed to determine the effects of PC-enriched virgin OO on reverse cholesterol transport (RevCT) from macrophages to feces in vivo. Female C57BL/6 mice were given intragastric doses of refined OO (ROO) and a functional unrefined virgin OO enriched with its own PC (FVOO) for 14 days. Our experiments included two independent groups of mice that received intragastric doses of the phenolic extract (PE) used to prepare the FVOO and the vehicle solution (saline), as control, for 14 days. FVOO intake led to a significant increase in serum HDL cholesterol and its ability to induce macrophage cholesterol efflux in vitro when compared with ROO group. This was concomitant with the enhanced macrophage-derived [ 3 H]cholesterol transport to feces in vivo. PE intake per se also increased HDL cholesterol levels and significantly promoted in vivo macrophage-to-feces RevCT rate when compared with saline group. PE upregulated the expression of the main macrophage transporter involved in macrophage cholesterol efflux, the ATP binding cassette a1. Our data provide direct evidence of the crucial role of OO PCs in the induction of macrophage-specific RevCT in vivo.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

DNA methylation biomarkers of myocardial infarction and cardiovascular disease

  • Fernández-Sanlés, Alba
  • Sayols-Baixeras, Sergi
  • Subirana, I.
  • Sentí, Mariano
  • Pérez-Fernández, S.
  • de Castro Moura, Manuel
  • Esteller, M|||0000-0003-4490-6093
  • Marrugat, Jaume|||0000-0003-3320-554X
  • Elosua, Roberto|||0000-0001-8235-0095
Background: The epigenetic landscape underlying cardiovascular disease (CVD) is not completely understood and the clinical value of the identified biomarkers is still limited. We aimed to identify differentially methylated loci associated with acute myocardial infarction (AMI) and assess their validity as predictive and causal biomarkers. Results: We designed a case-control, two-stage, epigenome-wide association study on AMI (n = 391, n = 204). DNA methylation was assessed using the Infinium MethylationEPIC BeadChip. We performed a fixed-effects meta-analysis of the two samples. 34 CpGs were associated with AMI. Only 12 of them were available in two independent cohort studies (n ~ 1800 and n ~ 2500) with incident coronary and cardiovascular disease (CHD and CVD, respectively). The Infinium HumanMethylation450 BeadChip was used in those two studies. Four of the 12 CpGs were validated in association with incident CHD: AHRR-mapping cg05575921, PTCD2-mapping cg25769469, intergenic cg21566642 and MPO-mapping cg04988978. We then assessed whether methylation risk scores based on those CpGs improved the predictive capacity of the Framingham risk function, but they did not. Finally, we aimed to study the causality of those associations using a Mendelian randomization approach but only one of the CpGs had a genetic influence and therefore the results were not conclusive. Conclusions: We have identified 34 CpGs related to AMI. These loci highlight the relevance of smoking, lipid metabolism, and inflammation in the biological mechanisms related to AMI. Four were additionally associated with incident CHD and CVD but did not provide additional predictive information.